Russell Investments Group Ltd. lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 27.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,264,877 shares of the medical equipment provider’s stock after buying an additional 274,893 shares during the period. Russell Investments Group Ltd. owned about 0.09% of Boston Scientific Corporation worth $36,889,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BSX. Janus Henderson Group PLC boosted its position in shares of Boston Scientific Corporation by 22,491.6% in the second quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares during the period. Jennison Associates LLC boosted its position in shares of Boston Scientific Corporation by 405.3% in the second quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after buying an additional 8,533,655 shares during the period. BlackRock Inc. boosted its position in shares of Boston Scientific Corporation by 4.6% in the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Boston Scientific Corporation by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after buying an additional 3,033,800 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Boston Scientific Corporation by 149.1% in the third quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares during the period. 90.68% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Maulik Nanavaty sold 57,031 shares of Boston Scientific Corporation stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $27.28, for a total value of $1,555,805.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific Corporation stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the transaction, the executive vice president now owns 164,681 shares in the company, valued at $4,647,297.82. The disclosure for this sale can be found here. Insiders sold 508,864 shares of company stock worth $14,581,669 over the last quarter. 0.74% of the stock is currently owned by corporate insiders.

Boston Scientific Corporation (NYSE BSX) traded up $0.09 during midday trading on Tuesday, reaching $28.35. The company’s stock had a trading volume of 3,410,600 shares, compared to its average volume of 6,602,495. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $38,810.00, a price-to-earnings ratio of 23.16, a P/E/G ratio of 2.18 and a beta of 0.99.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting analysts’ consensus estimates of $0.31. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.27 earnings per share. analysts forecast that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/boston-scientific-corporation-bsx-stake-increased-by-russell-investments-group-ltd/1717732.html.

Several analysts have recently commented on BSX shares. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific Corporation in a research report on Monday, September 25th. UBS AG reaffirmed a “buy” rating and issued a $31.00 target price (up previously from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. Cowen and Company reiterated a “buy” rating and set a $32.00 price objective (up from $31.00) on shares of Boston Scientific Corporation in a report on Friday, July 28th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $34.00 price objective on shares of Boston Scientific Corporation in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $30.77.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.